DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20204009

Mortality among the early cases of COVID-19 and its association with key comorbidities in a large state in South India

Suhas Bhat, Rohan Kolla, Shashank D. Shindhe, Surekha B. Munoli

Abstract


Background: The mortality associated with the pandemic COVID-19 is a subject of intense scrutiny as COVID-19 can cause severe disease leading to hospitalization in ICU and potentially death, especially in the elderly with comorbidities. A statistical analysis is carried out to study the impact of age, gender and comorbidities on deaths among early one lakh infected population of Karnataka, a large state in south India.

Methods: Daily case fatality rate and adjusted case fatality rate (CFR) (adjusted to median death time) are estimated. The impacts of age, gender and comorbidities on mortality outcomes of COVID patients are studied.

Results: The daily CFR on 27th July for Karnataka is estimated from the dataset to be 1.93%. However, the adjusted CFR based on the median number of days from diagnosis to death was found to be 2.15% (95% confidence interval 2%-2.3%) on that day. The deaths among male patients outnumber those in females. As far as age of the patients is concerned, more than 50% of the deaths occurred in the age group 50-60 and 60-70 years. Majority of deaths reported in the state were associated with at least one of the comorbidity. Diabetes mellitus and hypertension were the most significant comorbidities.

Conclusions: The daily adjusted CFR for the study region is found to be lower than the CFR of the whole nation. Also the age, gender and comorbidities were found to be associated with the deaths as opposed to the infection alone. It was also deduced that, patients with a history of diabetes or hypertension or ischemic heart disease or a combination of any of these were most likely to experience severe outcomes of the infection. 


Keywords


COVID-19, Case fatality rate, Comorbidities, Diabetes mellitus, Hypertension, Ischemic heart disease

Full Text:

PDF

References


World Health Organization. WHO characterizes covid-19 as a pandemic- 11 March 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed on 18 August 2020.

Coronavirus update (live): Worldometer. Available at: https:// worldometers.info/coronavirus/. Accessed on 4 September 2020.

COVID-19 information portal of the directorate of the health and family welfare services of the Government of Karnataka. Available at: https://covid19.karnataka.gov.in/govt_bulletin/en. Accessed on 4 September 2020.

Chang CS, Yeh YT, Chien TW, Lin JC, Cheng BW, Kuo SC. The computation of case fatality rate for novel coronavirus (COVID-19) based on Bayes theorem: An observational study. Medicine. 2020;99(21):e19925.

Bhat S, Munoli SB, Kolla R. Survival Analysis of SARS-COV-2 in infected population of Karnataka State of India. American Journal of PharmTech Research. 2020;10(4):197-204.

Coronavirus Pandemic (COVID-19): Our World in data. Available at: https://ourworldindata.org/ coronavirus. Accessed on 4 September 2020.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American statistical association. 1958;53(282):457-81.

Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan C, Neelima S, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. medRxiv. 2020. Available at: https://www. medrxiv.org/content/10.1101/2020.07.14.20153643v1.full.pdf. Accessed on 4 September 2020.

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A Nationwide Analysis. European Respiratory Journal. 2020;55(5): 2000547.

Singh AK, Misra A. Impact of COVID-19 and comorbidities on health and economics: focus on developing countries and India. Diabetes & metabolic syndrome Clinical Research & Reviews. 2020;14(6):1625-30.

García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, Talavera B, et al. Neurological comorbidity is a predictor of death in COVID-19 disease: a cohort study on 576 patients. Frontiers in neurology. 2020;11:781.

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health. Available at: https://www.sciencedirect.com/science/article/pii/S1876034120305943. Accessed on 4 September 2020.

Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A, et al. Comorbidity assessment is essential during COVID-19 treatment. Frontiers in Physiology. 2020;11:984.

Espinosa OA, Zanetti AD, Antunes EF, Longhi FG, Matos TA, Battaglini PF. Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Revista do Instituto de Medicina Tropical de São Paulo. 2020;62:e43.

Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. American American J Infection Control. 2020;S0196-6553(20):30637-4.

Abdollahi E, Champredon D, Langley JM, Galvani AP, Moghadas SM. Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. CMAJ. 2020;192(25):e666-70.